Moreover, some studies showed patients with HER2 wild-type tumors have positive OS compared with those tumors containing amplified HER2 due to benefit from anti-EGFR monoclonal antibody, and the targeted management may be an influential factor in patients with advanced CRC (Pietrantonio et al., 2017; Salvia, Lopez-Gomez & Garcia-Carbonero, 2018). This evidence concerns the gene ERBB2 and colorectal carcinoma.